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Abstract: 
Background: Cancer survivorship following cancer treatment is 
uncertain as physical and psychological sequelae related to the 
disease or its treatment may persist. However, little is known about 
the experience of symptoms after treatment. 
  
Objectives: The purposes of this study were to (1) examine 
postchemotherapy (post-CTX) symptom trajectories in cancer 
survivors and (2) determine whether demographic characteristics 
predicted symptom trajectories. 
  
Methods: One hundred patients who recently completed CTX for 
lung cancer, colorectal cancer, or lymphoma rated symptoms on an 
electronic patient care monitor system prior to ambulatory care 
visits. Latent growth curve analyses were conducted to examine 
the trajectories of pain, fatigue, sleep disturbance, distress, and 
depression for 16 months after initial CTX. 
  
Results: Symptoms were present at the first follow-up visit 
following CTX (P < .0001) and persisted over 16 months. The 
depression trajectory was predicted by sex: males showed a 
convex curvilinear growth trajectory, whereas females showed a 
concave trajectory (P < .05). Higher distress was predicted by 
  
younger age (P < .05). 
Conclusions: Psychological and physical symptoms persisted over 
the 16-month period following CTX for the entire sample. Sex 
differences in coping could partially explain the different 
trajectories of growth for depression, but further studies are 
warranted. Younger patients may be more vulnerable for distress 
during this posttreatment phase. 
  
Implications for Practice: The posttreatment surveillance plan for 
cancer survivors should include a comprehensive assessment of 
psychological and physical symptoms. Persistence of symptoms 
can be expected in some patients, and supportive interventions 
should be tailored according to symptom reports. 
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Article: 
More than 10 million cancer survivors live in the United States. Cancer survival rates have 
tripled over the past 30 years, primarily due to earlier detection and advances in cancer 
treatment.1 Cancer survivorship is a dynamic experience that ebbs and flows through various 
phases and transitions. One of the most challenging and worrisome transitions is the one from 
active cancer treatment to follow-up. Even though cancer treatment is either temporarily or 
permanently completed, patients may continue to experience physical and psychosocial sequelae 
associated with cancer and its treatment.2 According to the National Coalition for Cancer 
Survivorship and the National Cancer Institute's Office of Cancer Survivorship, a cancer survivor 
is any individual who has been diagnosed with cancer.3 This trajectory extends from the time of 
diagnosis throughout the balance of one's life. For this study, posttreatment survivors were 
considered those individuals who have completed primary cancer treatment, regardless of stage 
of disease. 
  
Pain, fatigue, and sleep disturbance are common adverse effects in posttreatment survivors.2,4,5 
Symptoms can be related to the disease itself, cancer treatment, or a nonmalignant cause. A 
handful of studies have evaluated the physical symptoms of cancer survivors. Patients with a 
history of breast cancer 6 and Hodgkin disease 7 reported fatigue for months after the completion 
of therapy. Disease-free patients with rectal cancer experienced residual pain and constipation.8 
Sixty-two percent of lung cancer survivors had postthoracotomy pain 6 months after surgery,9 
and insomnia was reported by 30% of cancer survivors up to 11 years after diagnosis.10 These 
cross-sectional studies measured symptoms at varying time points and did not examine the 
intensity or trajectories of symptoms along the survivorship trajectory. Only 1 cross-sectional 
study was found that reported fatigue intensity among a physically active cohort of survivors in 
active treatment and posttreatment.11 Mean levels of fatigue were reported at 3.0 (scale range 
from 1= not at all to 5= extremely). 
  
Psychological effects including depressed mood and distress are additional concerns during the 
treatment transition. Fear of recurrence, financial distress, changes in family dynamics, and 
uncertainty about the future all contribute to the emotional distress of the survivor.2 Depressed 
mood and distress may also contribute to more intense fatigue and sleep disturbances.2,5 In fact, 
psychological morbidity was shown to persist in some posttreatment cancer survivors. For 
example, survivors of colorectal cancer and Hodgkin disease were found to be at increased risk 
for psychological distress.12,13 Other studies found that individual characteristics such as 
younger age, preexisting depressed mood, distress, other comorbidities, and a lack of social 
support predicted the presence psychological morbidity in patients with breast cancer 14-21 and 
prostate cancer.22-24 
  
Only 2 longitudinal studies examined symptoms in posttreatment survivors. Higher stage of 
disease, more comorbidities, and lung cancer were significant predictors of pain and fatigue in 
elderly cancer survivors in the year after their cancer diagnosis.25 Another study found 5 distinct 
patterns of depressed mood in women with breast cancer who were evaluated after treatment and 
at 3 and 6 months. In addition, an increased number of children at home predicted more 
depressed mood.26 
  
Although pain, fatigue, sleep disturbance, depression, and distress are reported symptoms in 
posttreatment survivors, little research is available regarding the intensity and posttreatment 
trajectories of these symptoms over time. Understanding how symptoms change in the 
immediate posttreatment period, whether they worsen or improve over time, the rate or type of 
change that occurs, and which patients are at higher risk for persistent symptoms can assist 
clinicians in prevention and management strategies during the posttreatment follow-up period. 
 
 Furthermore, this study examined symptoms among cancer survivors with 3 cancer diagnoses 
(ie, lung cancer, colorectal cancer, lymphoma) that have not been investigated routinely. The 3 
types of cancer in this study comprise 31% of all malignancies 27 in all stages of disease. The 
incidence and survival rates for these 3 malignancies are increasing, even in late-stage disease. 
The increase in 5-year survival for all stages of lung cancer is modest, 13% to 16% in the last 30 
years, but survival is increasing in earlier stages of the disease. The 5-year survival rate of non-
Hodgkin lymphoma and colorectal cancer is 65%, making colorectal cancer survivors the third 
largest cancer survivorship population. Finally, as previously reported, the transition period from 
primary cancer treatment to cancer surveillance is an especially vulnerable transition period for 
cancer survivors and warrants further investigation.27 
  
Therefore, the aims of this study were (1) to examine the postchemotherapy (post-CTX) 
symptom experience (ie, pain, fatigue, sleep disturbance, depressed mood, distress) for the first 
16 months after treatment in patients who were newly diagnosed with lymphoma, colorectal 
cancer, or lung cancer and (2) to determine whether demographic (ie, age, sex, race and 
ethnicity, marital status, education, religion) and clinical characteristics (ie, co-morbid 
conditions, type of cancer, stage of disease, type of therapy) predicted trajectories of symptom 
change. This study used latent growth curve analyses (LGCAs) to answer the following research 
questions: 
  
(1) What was the baseline mean (intercept) and trajectory (mean, intercept, slope, or quadratic 
curve) for each symptom for the entire sample? 
  
(2) What was the average trajectory of change and degree of interindividual variation for the 
posttreatment symptoms? 
  
(3) To what extent were demographic and clinical characteristics associated with posttreatment 
trajectories (intercept, slope, or quadratic term)? 
  
Theoretical Framework 
 The Symptoms Experience Model 28 served as the theoretical framework for this study. The 
model takes into account the global cancer symptom experience. Antecedents of the model 
include demographic characteristics that can affect the symptom experience such as age, sex, and 
race/ethnicity. Other antecedents include disease characteristics such as the type of cancer, the 
cancer treatment, and related medical factors including comorbid conditions. Together, the 
antecedents influence or moderate input into the symptom experience. The symptom experience, 
individually defined by the patient, includes characteristics such as frequency, intensity, distress, 
and meaning. The symptoms in this study included pain, fatigue, depressed mood, distress, and 
sleep disturbances. Although not included in this study, the consequences of the Symptoms 
Experience Model include overall adjustment to the illness, quality of life, functional status, 
disease progression, and survival. 
 
 Patients and Methods 
Sample 
 The sample included 100 patients with lung cancer (n = 41), colorectal cancer (n = 28), or 
lymphoma (n = 31) who received CTX at the Hematology Oncology Centers of the Northern 
Rockies outpatient clinic from June 2004 through March 2007. These malignancies were chosen 
because of similar age and sex distributions and because few studies have examined symptoms 
specific to these malignancies. Although the sample used in this study was limited to 1 outpatient 
oncology clinic, it included the entire population of clinic patients who recently had completed 
CTX for the 3 diagnoses. Patients self-reported symptom data in the waiting room prior to an 
ambulatory visit on a handheld electronic patient care monitor (PCM). 
 
  
The initial sample consisted of 532 patients who represented 4287 points in time, screened for 
the following inclusion criteria: (1) patients who had completed an initial course of CTX for 
newly diagnosed lymphoma, colorectal cancer, or lung cancer and (2) patients who had at least 4 
measures after the completion of CTX in the PCM database. Patients excluded from the study 
were those whose surveillance visits were not associated with initial CTX and whose CTX 
course and cycle records were not available. 
 
 Data Collection Tool 
 The data set was part of the AIM (Assessment Information Management) Higher clinical 
initiative to improve the assessment, documentation, and management of cancer symptoms in 
adult outpatients.29 The initiative includes a unique data collection system in which patients rate 
symptom experiences via a handheld electronic tablet called the PCM. Table 1 includes an 
overview of the data-entry procedures. The PCM has undergone rigorous psychometric testing. 
Internal consistency was examined for 6 subscales and for the total quality-of-life scale of the 
PCM. Cronbach [alpha] ranged from .80 to .89.30 Hematology Oncology Centers of the 
Northern Rockies was an initial [alpha] site for this initiative and began data collection in June 
2004. The program is now a part of Supportive Oncology Services. 
 
 Table 1 has been omitted from this formatted document.   
Patients entered demographic and disease-related variables into the PCM at the initial outpatient 
visit. Nine of these variables were used in this study: age, sex, type of cancer, stage of disease, 
comorbidities, marital status, education level, race, and religion. Comorbidities were verified 
through chart review. A total of 38 physical and psychological symptoms were entered into the 
original PCM that underwent 2 revisions, which resulted in 86 items. Patients self-reported 
symptoms in the PCM during each outpatient visit but no more than once every 2 weeks. Each 
symptom was rated on a scale from 0 to 10, with 0 = not a problem, 1 to 3 = mild problem, 4 to 6 
= moderate problem, 7 to 9 = severe problem, and 10 = as bad as possible. The numeric ratings 
appeared on the screen in conjunction with verbal anchor cues. Pain, fatigue, and sleep 
disturbance were measured using a single item. Depressed mood (7 items) and distress (4 items) 
were measured using 2 separate subscales. The subscales were converted to normalized T scores 
based on a comparative reference group of heterogeneous ambulatory oncology patients (n = 
449) from the West Clinic in Memphis, Tennessee.31 
 
  
Data Download and Cleaning 
 Following approval from the Inter-institutional Review Board of Billings, Montana, the data 
were downloaded to the principal investigator's locked personal computer into SPSS for 
Windows. The download included 532 patients with lung cancer, colorectal cancer, or lymphoma 
representing 4287 points in time. Patients in the database were matched to paper and other 
electronic records at the Hematology Oncology Centers of the Northern Rockies clinic. These 
records were screened by hand for inclusion criteria. Reasons for ineligibility were wrong 
diagnosis (n = 27), treated for relapsed disease (n = 53), no CTX (n = 222), unavailable CTX 
cycle data (n = 37), and less than 3 follow-up visits post-CTX (n = 91). For eligible patients, 3 
additional time points were inserted into the database and indicated (1) CTX cycle number, (2) 
the day of each CTX cycle, and (3) follow-up visits after initial CTX. An Access (Microsoft) 
database was created to manage variables not included in the PCM such as types of CTX, 
medications, and stage of disease.32 Additional data were extracted from the paper record 
including verification of comorbidities, stage of disease, and type of therapy (ie, CTX, radiation 
therapy, combined therapy). 
  
Because of the variability in surveillance times for each patient, data were reviewed for temporal 
distances between visits. Consideration was made for various follow-up schedules and the 
potential for late visits. The goal was to retain data for as many posttreatment visits as possible 
for the 16-month follow-up period. The final follow-up periods were included as time points in 
the analysis: 2 to 6 weeks, 6 to 14 weeks, 14 to 28 weeks, 28 to 42 weeks, 42 to 56 weeks, and 
56 to 70 weeks. If 2 visits were conducted within the follow-up period, the earliest visit was 
discarded, and the later visit was retained due to programming restraints in MPlus.33 
 
  
Statistical Analysis 
 Descriptive statistics and LGCAs were conducted using SPSS 12.0 for Windows 34 and MPlus 
5.0,33 respectively, to answer the research questions in this study. The means, SDs, and variance 
for each symptom were examined during each surveillance interval. Latent growth curve 
analyses were used to examine posttreatment symptoms and to determine if demographic or 
disease-related characteristics predicted distinct symptom trajectories. The first surveillance visit 
following treatment represented the intercept of the growth curve for each patient. The rate of 
change for each symptom over the surveillance periods was measured by the linear (slope) or 
quadratic parameter depending on the shape of the growth trajectory. 
 
 Initially, the 5 continuous individual symptom variables (ie, pain, fatigue, sleep, depressed 
mood, distress) were modeled unconditionally, that is, without the influence of predictor 
variables. The intercepts were fixed to zero and represented time 1 (ie, 2 to 6 weeks after the last 
CTX treatment). Linear and quadratic models were compared for best fit according to 
recommendations in the literature.35-39 A nonsignificant [chi]2 value, a comparative fit index 
greater than 0.90, and a Tucker Lewis Index greater than 0.95 were used as the fit statistics with 
the greatest weight. A Tucker Lewis Index of greater than 1 was a potential sign that the model 
was overfit. Other fit measures included root-mean-square error of approximation of less than 
0.06 for a good fit and 0.06 to 0.08 for a fair fit and a standard root-mean-square residual of less 
than 0.08. 
  
Each of demographic and clinical characteristics was individually loaded into the symptom 
models to test for covariation. Specifically, these conditional models examined potential 
predictors of the posttreatment symptom trajectories. Age, comorbidities, and stage of disease 
were entered as continuous variables. All other variables (ie, sex, type of cancer, marital status, 
educational level, race and ethnicity, religion) were categorical, which resulted in collapsing 
some variables. Those collapsed and recoded included type of cancer coded as lung cancer or 
not, married/partnered or not, white or nonwhite and Hispanic, and high school diploma or less 
versus more than high school. The significance level for the unconditional and conditional 
models was set at P < .05. 
 
  
Results 
Patient and Clinical Characteristics 
 The demographic and clinical characteristics of the sample are included in Table 2. Slightly 
more males than females (56% vs 44%) were included in the sample, with a mean age of 62.9 
(SD, 12.63) years (range, 24-84 years). More than half were married or partnered (67%), and the 
majority was white (91%). A high-school degree or less existed in 57% of the sample. More than 
one-third of the patients had lung cancer (41%), and 42% of the patients had stage IV cancer. 
The mean number of comorbidities for the sample was 2.24 (range, 0-6); 73% of the sample had 
at least 1 comorbidity. The most common comorbidities were hypertension (31%), gastric 
problems such as gastrointestinal esophageal reflux disorder (21%), cardiac problems (18%), and 
chronic obstructive pulmonary disease (14%). Whereas 70% of the patients had received CTX 
alone, 18% received concurrent CTX and radiation therapy, and 12% had received radiation 
therapy during this follow-up. CHOP (cyclophosphamide, doxorubicin, oncovin, prednisone) 
with or without rituximab was the most common CTX used for patients with lymphoma. For 
colorectal cancer, FOLFOX (5-FU, oxaliplatin, and leucovorin) and less commonly FOLFIRI (5-
fluorouracil, irinotecan, leucovorin) were given for colorectal cancer. Lung cancer had the 
greatest variability of CTX regimens administered and included cisplatin/etoposide, 
carboplatin/paclitaxel, carboplatin/docetaxel), and cisplatin/carboplatin. Avastin was also used in 
conjunction with some of the lung cancer regimens. 
 
Table 2 has been omitted from this formatted document. 
   
Symptom Intensity Post-CTX 
 Table 3 includes a summary of the percentage of patients with each symptom along with the 
means and SDs of symptom severity scores over the follow-up times. Depressed mood scores 
stayed close to the normalized mean of 50 (SD, 10) for the entire sample. However, variance 
(range, 58.71-84.56) was statistically significant, which suggests that some patients were 
depressed. Distress scores were also not significantly different from the mean of 50. However, 
the distress scores exhibited greater variance (range, 92.53-109.03) than depressed mood scores. 
The highest level of fatigue was reported at time 1, the first follow-up visit after CTX. Whereas 
fatigue and pain scores fluctuated throughout the follow-up times, the overall trend decreased 
over time (2.25 to 1.70 for fatigue and 3.87 to 2.67 for pain). Interestingly, pain had the highest 
mean score of any symptom at time 1. The mean scores for sleep disturbance were less than 2 for 
all follow-up times and had less variability over time than the other symptoms. 
 
 Table 3 has been omitted from this formatted document.   
Fit Statistics for the Growth Curve Models 
 Growth curve modeling for each symptom was conducted in MPlus 5.0,33 and linear and 
quadratic models were compared for best fit. Fit statistics were examined to determine whether 
data fit a linear or quadratic pattern. Model fit was unstable over 6 points in time for depressed 
mood, fatigue, and sleep disturbance. These models were rerun using the first 4 and 5 time 
points. Depressed mood showed a good quadratic fit over 4 time points. Both fatigue and sleep 
disturbance resulted in a linear fit over 4 follow-up time points. Models for distress and pain 
were stable over 6 points in time. Whereas distress demonstrated a quadratic growth trajectory, 
pain showed a linear growth. 
 
 Unconditional Symptom Models 
 Table 4 lists the estimates, SEs, and levels of significance for the unconditional models, that is, 
the data modeled without predictor variables. Intercepts were significant (P < .0001) for all 
symptoms indicating a significant presence of symptoms at the intercept (time 1 follow-up). 
Significant variances at the intercepts (P < .01) occurred for all symptoms except for sleep 
disturbance, which suggests a high degree of interindividual variability in symptoms at the 
intercept or a wide range of intensity scores. 
 
 Table 4 has been omitted from this formatted document.   
None of the symptom slope or quadratic terms were significantly different from zero. This 
finding indicates a lack of change in symptom severity scores during the posttreatment trajectory. 
Interpretation of this finding suggests that symptom intensity persisted throughout the 
posttreatment follow up visits for the entire sample. The variance was significant for the 
quadratic estimates for depressed mood (P < .01) and distress (P = .02) and for the slope of 
fatigue (P < .01), which indicates interindividual variability around the posttreatment trajectories. 
Therefore, a wide range of symptom intensity was experienced by the sample. The variability in 
depressed mood scores is illustrated in Figure 1 as an example of individually varying 
trajectories. Figure 1A illustrates the variability of the depressed mood trajectories of 10 patients. 
Because of the normalized T scoring, there is a floor effect for depressed mood at 42.92, 
indicating all zeros in the responses for depressed mood. Figure 1B illustrates the variability in 
the depressed mood scores for the entire sample. 
 
 Figure 1 has been omitted from this formatted document.  
Conditional Symptom Models: Predictors of Symptom Trajectories 
Depressed Mood 
 Conditional models were constructed on each symptom to determine whether covariates 
predicted the posttreatment growth curve symptom trajectories (Table 5). The quadratic growth 
curve for depressed mood was predicted by sex (P < .05). As shown in Figure 2, the shape of the 
trajectory for men was convex curvilinear, indicating an increase in depressed mood initially and 
then a decrease by time 4 (42 weeks). Women had an opposite concave curvilinear trajectory 
with depressed mood scores decreasing initially and then increasing by the end of time 4. 
Variance in depressed mood scores at time 1 (intercept) was predicted by race (P < .05). White 
patients had a mean depressed mood score of 47.68 (SD, 7.52) compared with nonwhite and 
Hispanic patients (n = 9), whose mean depressed mood score at time 1 was 54.54 (SD, 10.91) 
(Table 6). 
 
Table 5-6 and Figure 2 have been omitted from this formatted document. 
Distress 
 Age was a significant predictor of distress at time 1 (P < .01). For each 1-year increase in age, 
distress scores decreased by 0.58. The mean distress score at time 1 for patients younger than 65 
years was 48.74 (SD, 9.72), whereas the mean score for those older than 65 years was 44.61 (SD, 
9.16). 
 
Pain 
 Significant predictors of pain intensity at the intercept were cancer diagnosis and stage of 
disease (P < .001 and P < .05, respectively). Patients with lung cancer had a mean pain score of 
4.88 (SD, 2.03) at the intercept compared with a mean pain score of 2.94 (SD, 2.11) in patients 
with colorectal cancer and lymphoma. Pain was also highest in those with stage III (mean, 4.16; 
SD, 2.11) and stage IV (mean, 4.13; SD, 2.36) disease compared with patients with stage I (2.67; 
SD, 1.15) and stage II (mean, 2.7; SD, 2.16) disease. Race/ethnicity also predicted pain intensity 
at the intercept (P < .05). Nonwhite and Hispanic patients had a mean pain score of 5.11 (SD, 
2.47) compared with white patients (mean, 3.68; SD, 2.21). Upon further examination, no 
demographic or clinical differences were found between nonwhite and Hispanic patients and 
white patients in regard to type of cancer or stage of disease. 
 
Fatigue 
Fatigue was not predicted by any of the demographic characteristics evaluated in this study. 
 
Sleep Disturbance 
  
Race (P < .05) and religion (P < .01) were significant predictors of fatigue severity at the 
intercept. White patients had a mean score of 1.25 (SD, 2.0), and nonwhite and Hispanic patients 
had a mean score of 2.22 (SD, 2.82). The patients who claimed no religion or a non-Catholic or 
non-Protestant faith had a mean sleep disturbance score of 3.15 (SD, 3.31) compared with 
Catholic and Protestant patients, who had a mean score of 0.96 (SD, 1.77). 
 
Discussion 
This study examined symptom trajectories of pain, fatigue, sleep disturbance, depressed mood, 
and distress in posttreatment cancer survivors and investigated whether demographic and 
disease-related variables predicted the distinct posttreatment symptom growth curve trajectories. 
Unlike previous research, this longitudinal study used a clinical symptom monitoring tool (PCM) 
and used LGCAs to examine symptoms after CTX treatment beyond the first year of 
posttreatment survival. 
 
 None of the linear or quadratic terms were significant for the entire sample, indicating that the 
trajectories were not significantly different than zero. These near-flat line trajectories suggest 
that overall symptom severity scores remained the same over the 16-month posttreatment period. 
However, all of the symptoms, except sleep, demonstrated significant variance in the intercepts 
and/or growth trajectories, which suggests a large amount of interindividual variability in these 
symptom trajectories. This finding is similar to those reported by Miaskowski and colleagues 40 
for fatigue in patients who underwent radiation therapy for prostate cancer. 
  
The quadratic shapes for depressed mood were significantly predicted by sex. Whereas men had 
an increase in depressed mood at midyear after treatment (convex curve), women exhibited a 
decrease in depressed mood at midyear (concave curve) (Figure 2). Further exploration of this 
phenomenon revealed no significant differences in diagnosis between men and women, but 
significantly more men had stage IV disease. It is possible that the different trajectories are due 
to different stages of disease or differences in coping and psychological adjustment between men 
and women in respect to uncertainty about the future, fear, role adjustment, finances, and other 
survivorship issues. 
  
The published literature sheds some light on sex differences in depression in oncology patients, 
but findings are inconsistent.41 Some studies reported no sex differences in the prevalence 42,43 
or severity 41,44 of depression, whereas others found an increase in the prevalence of depression 
in women when compared with men.43,45 Two studies reported more depression in elderly 
women.46,47 A handful of other studies also examined long-term depression and psychological 
adjustment in cancer survivors, but none reported information on sex differences.26,48,49 
Further investigation regarding sex differences in oncology patients' depression trajectories is 
warranted. Depressed mood was also predicted by race/ethnicity. However, the small number of 
nonwhite and Hispanic patients limits discussion and comparison with other studies of diverse 
populations. 
 
 Distress was predicted by a younger age at the first follow-up visit. The transition from 
treatment to posttreatment survivor was noted as a time of significant distress in the Institute of 
Medicine report, "From Cancer Patient to Cancer Survivor: Lost in Transition."2 In addition, 
previous findings suggest that younger age is a risk factor for distress and psychological 
adjustment following a cancer diagnosis.14,18,22,50 However, these studies consisted of 
patients with breast cancer, study designs were cross-sectional, and only 1 study examined 
patients after treatment.18 
 
 Although pain decreased slightly over time for the entire sample, this downward trend was not 
statistically significant. Given et al 25 found that pain and fatigue decreased over time in the first 
year after diagnosis. Samples and methodologies of the studies are different in that Given et al 25 
included elderly oncology patients with various cancer diagnoses and reported pain prevalence, 
whereas this study reported pain intensity in 3 specific diagnoses without age limitation. 
  
The mean pain score of 3.87 at the first follow-up visit posttreatment was the highest intensity of 
any symptom. It is unknown whether this pain was disease related, treatment related, or related 
to a nonmalignant cause. However, 42% of patients had stage IV disease, and pain was predicted 
by a higher stage of disease and by lung cancer in this study. Whereas advanced disease may be 
an explanation for the increased pain intensity, a study by Senturk et al 9 found that 62% of lung 
cancer survivors 6 months after surgery experienced postthoracotomy pain, and residual pain and 
constipation were found to be a long-term effect in patients with rectal cancer.8 In addition, 
many CTX agents used to treat the 3 malignancies in this study are neurotoxic.51-55 One study 
noted an occurrence rate of 38% for sensory neuropathy in a group of patients treated for lung 
cancer.56 It is unknown whether patients interpreted neuropathy as pain in their PCM symptom 
reports, but more studies are needed to determine the types of pain that patients experience after 
treatment. Patients in this study received a variety of neurotoxic agents including cisplatin, 
oxaliplatin, vincristine, paclitaxel, and docetaxel. 
  
Pain intensity was predicted by younger age at the intercept in this study. One published study 
examined the age-related experience of pain, nausea, and vomiting in patients with cancer and 
found that elderly patients reported less severe symptoms, although the correlations between age 
and symptoms were moderate to weak (pain, r = -0.22; nausea and vomiting, r = -0.43).57 It is 
possible that a response shift occurs in the elderly as they learn to live with cancer and its 
associated sequelae,58 although more research is needed in this area. 
 
 A higher pain intensity score was significantly predicted by nonwhite race and Hispanic 
ethnicity at the first follow-up visit. This finding is consistent with previous reports that minority 
patients report more pain than white patients.59,60 For example, Beck and Falkson 60 found that 
blacks had a higher prevalence of pain (56.1% compared with 29.4%), and 81% of blacks 
experienced moderate to severe pain compared with 65% of whites. However, generalizability is 
limited because of the small number of nonwhite and Hispanic patients in the study. 
 
 Sleep disturbance was the only symptom to show a slight increase over the 16 months of this 
study, but the trajectory of sleep disturbance was not significantly different than zero. It is 
important to note that pain, depressed mood, and sleep disturbance were predicted by 
race/ethnicity in this study. Other studies have noted that these symptoms often coexist.44,61-63 
Interestingly, race/ethnicity did not predict fatigue, another symptom often found within that 
cluster, but overall fatigue intensity was higher for nonwhite and Hispanic patients. However, 
this analysis did not cluster patients, an important difference in study designs. Because the slopes 
of the 3 symptoms in this study were not significantly different from zero (flat line trajectory), 
nonwhite and Hispanic patients had more intense symptoms throughout the follow-up periods. 
 
 Although this study has presented some significant findings, several limitations are noted. First, 
although the time points were used to identify follow-up visits, the analysis could incorporate 
only 1 visit per follow-up time, which led to the loss of some data. More frequent assessments 
may result in different symptom trajectories. Second, although the heterogeneity of the sample 
increased generalizability, the different stages of disease and the wide array of CTX regimens 
and symptom management medications used may have influenced the results, and these variables 
were not included in the analysis. In particular, the CTX agents may have contributed to different 
pain, fatigue, and sleep disturbance trajectories. Third, a lack of racial and ethnic diversity was a 
limitation in this study. Whereas 91% of the patients were white, this distribution is 
representative of the Montana population. Therefore, study findings regarding race and ethnicity 
should be interpreted cautiously. 
  
Finally, the depressed mood and distress scales use normalized T scores that can be difficult to 
interpret. Because they are normalized according to a cancer population, it may appear that the 
sample was not distressed or depressed. However, on closer look, the significant variance 
indicated that there was a wide range of growth trajectories for individual patients, with some 
being distressed or depressed. Approximately 7% to 9% of the sample had a score of 1.5 SD 
above the depressed mood and distress means, respectively. 
  
Future opportunities for research are plentiful. First, the sex differences in depressed mood 
trajectories warrant further investigation. Studies that examine specific aspects of psychological 
adjustment such as financial stress, work-related issues, and coping styles should be conducted. 
Second, the majority of growth trajectory parameters (slope and quadratic) were not significantly 
different from zero, indicating a flat curve. This finding suggests that that for many patients, 
symptoms persist after CTX. Future studies should focus on which patients have an improvement 
in symptoms and which patients continue to experience physical and psychological symptoms as 
some patients may not recover. Overall, more research is needed with clinical database 
repositories. These data can provide valuable information regarding patient experiences in the 
clinical setting, but databases may need revision to be conducive to both patient needs and 
research objectives. 
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